ORAGENICS INC — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAGENICS INC (OGEN)
CIK: 0001174940
Period of Report: 2021-01-02

Reporting Person: KOSKI ROBERT C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-02	Common Stock	G	30000	—	Disposed	212839	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-18	Non-Employee Director Option (Right to Buy)	$1.20	A	160000	Acquired	2031-02-18	Common Stock (160000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	776483	Indirect
Common Stock	53086	Indirect

Footnotes

F1: Shares owned directly by Robert C. Koski, a director of the Company.

F2: Represents shares owned by the Koski Family Limited Partnership ("KFLP"). The reporting person serves as one of the general partners of the KFLP and disclaims beneficial ownership of the securities reflected as held by the KFLP except to the extent of the reporting person's pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.

F3: Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (10,760 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (10,760 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (10,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (10,760 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (10,806 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.

F4: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021.